Mostrar el registro sencillo del ítem
dc.contributor.author | Rose, Angela Mc | |
dc.contributor.author | Nicolay, Nathalie | |
dc.contributor.author | Sandonis-Martin, Virginia | |
dc.contributor.author | Mazagatos, Clara | |
dc.contributor.author | Petrović, Goranka | |
dc.contributor.author | Niessen, F Annabel | |
dc.contributor.author | Machado, Ausenda | |
dc.contributor.author | Launay, Odile | |
dc.contributor.author | Denayer, Sarah | |
dc.contributor.author | Seyler, Lucie | |
dc.contributor.author | Baruch, Joaquin | |
dc.contributor.author | Burgui, Cristina | |
dc.contributor.author | Loghin, Isabela I | |
dc.contributor.author | Domegan, Lisa | |
dc.contributor.author | Vaikutytė, Roberta | |
dc.contributor.author | Husa, Petr | |
dc.contributor.author | Panagiotakopoulos, George | |
dc.contributor.author | Aouali, Nassera | |
dc.contributor.author | Dürrwald, Ralf | |
dc.contributor.author | Howard, Jennifer | |
dc.contributor.author | Pozo Sanchez, Francisco | |
dc.contributor.author | Sastre-Palou, Bartolomé | |
dc.contributor.author | Nonković, Diana | |
dc.contributor.author | Knol, Mirjam J | |
dc.contributor.author | Kislaya, Irina | |
dc.contributor.author | Luong Nguyen, Liem Binh | |
dc.contributor.author | Bossuyt, Nathalie | |
dc.contributor.author | Demuyser, Thomas | |
dc.contributor.author | Džiugytė, Aušra | |
dc.contributor.author | Martínez-Baz, Iván | |
dc.contributor.author | Popescu, Corneliu | |
dc.contributor.author | Duffy, Róisín | |
dc.contributor.author | Kuliešė, Monika | |
dc.contributor.author | Součková, Lenka | |
dc.contributor.author | Michelaki, Stella | |
dc.contributor.author | Simon, Marc | |
dc.contributor.author | Reiche, Janine | |
dc.contributor.author | Otero-Barrós, María Teresa | |
dc.contributor.author | Lovrić Makarić, Zvjezdana | |
dc.contributor.author | Bruijning-Verhagen, Patricia Cjl | |
dc.contributor.author | Gomez, Verónica | |
dc.contributor.author | Lesieur, Zineb | |
dc.contributor.author | Barbezange, Cyril | |
dc.contributor.author | Van Nedervelde, Els | |
dc.contributor.author | Borg, Maria-Louise | |
dc.contributor.author | Castilla, Jesús | |
dc.contributor.author | Lazar, Mihaela | |
dc.contributor.author | O'Donnell, Joan | |
dc.contributor.author | Jonikaitė, Indrė | |
dc.contributor.author | Demlová, Regina | |
dc.contributor.author | Amerali, Marina | |
dc.contributor.author | Wirtz, Gil | |
dc.contributor.author | Tolksdorf, Kristin | |
dc.contributor.author | Valenciano, Marta | |
dc.contributor.author | Bacci, Sabrina | |
dc.contributor.author | Kissling, Esther | |
dc.contributor.author | MOVECOVID- 19 hospital study team | |
dc.contributor.author | VEBIS hospital study team | |
dc.date.accessioned | 2023-12-13T10:46:45Z | |
dc.date.available | 2023-12-13T10:46:45Z | |
dc.date.issued | 2023-11 | |
dc.identifier.citation | Euro Surveill. 2023 Nov;28(47):2300186. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16792 | |
dc.description.abstract | Introduction: Two large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. Aim: We aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021. Methods: Forty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. Results: We included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose < 90 days before onset; ≥ 70% in those 90-179 days before onset. Conclusions: Our results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | European Centre for Disease Prevention and Control (ECDC) | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Alpha | es_ES |
dc.subject | Delta | es_ES |
dc.subject | Europe | es_ES |
dc.subject | SARS-CoV-2 | es_ES |
dc.subject | Hospital | es_ES |
dc.subject | Vaccine effectiveness | es_ES |
dc.subject.mesh | COVID-19 | es_ES |
dc.subject.mesh | Humans | es_ES |
dc.subject.mesh | Adult | es_ES |
dc.subject.mesh | BNT162 Vaccine | es_ES |
dc.subject.mesh | RNA, Viral | es_ES |
dc.subject.mesh | SARS-CoV-2 | es_ES |
dc.subject.mesh | Vaccine Efficacy | es_ES |
dc.subject.mesh | Hospitalization | es_ES |
dc.subject.mesh | Europe | es_ES |
dc.title | Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 37997666 | es_ES |
dc.format.volume | 28 | es_ES |
dc.format.number | 47 | es_ES |
dc.format.page | 2300186 | es_ES |
dc.identifier.doi | 10.2807/1560-7917.ES.2023.28.47.2300186 | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1560-7917 | es_ES |
dc.relation.publisherversion | https://doi.org/10.2807/1560-7917.ES.2023.28.47.2300186 | es_ES |
dc.identifier.journal | Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Epidemiología | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |